CELZ
Price
$1.03
Change
+$0.06 (+6.19%)
Updated
Sep 25 closing price
Capitalization
6.79M
66 days until earnings call
Intraday BUY SELL Signals
GNPX
Price
$3.29
Change
-$0.23 (-6.53%)
Updated
Sep 25 closing price
Capitalization
2.7M
Intraday BUY SELL Signals
Interact to see
Advertisement

CELZ vs GNPX

CELZ vs GNPX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CELZ vs. GNPX commentary
Sep 27, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELZ is a Hold and GNPX is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
CELZ vs GNPX: Fundamental Ratings
CELZ
GNPX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
8695
P/E GROWTH RATING
1..100
4894
SEASONALITY SCORE
1..100
24n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GNPX's Valuation (5) in the Pharmaceuticals Major industry is significantly better than the same rating for CELZ (74) in the null industry. This means that GNPX’s stock grew significantly faster than CELZ’s over the last 12 months.

GNPX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CELZ (100) in the null industry. This means that GNPX’s stock grew similarly to CELZ’s over the last 12 months.

CELZ's SMR Rating (98) in the null industry is in the same range as GNPX (100) in the Pharmaceuticals Major industry. This means that CELZ’s stock grew similarly to GNPX’s over the last 12 months.

CELZ's Price Growth Rating (86) in the null industry is in the same range as GNPX (95) in the Pharmaceuticals Major industry. This means that CELZ’s stock grew similarly to GNPX’s over the last 12 months.

CELZ's P/E Growth Rating (48) in the null industry is somewhat better than the same rating for GNPX (94) in the Pharmaceuticals Major industry. This means that CELZ’s stock grew somewhat faster than GNPX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELZGNPX
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
78%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
86%
Bullish Trend 5 days ago
76%
Declines
ODDS (%)
Bearish Trend 18 days ago
85%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
COMPARISON
Comparison
Sep 27, 2026
Stock price -- (CELZ: $1.03 vs. GNPX: $3.29)
Brand notoriety: CELZ and GNPX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELZ: 5% vs. GNPX: 74%
Market capitalization -- CELZ: $6.79M vs. GNPX: $2.7M
CELZ [@Biotechnology] is valued at $6.79M. GNPX’s [@Biotechnology] market capitalization is $2.7M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.37B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELZ’s FA Score shows that 0 FA rating(s) are green while GNPX’s FA Score has 1 green FA rating(s).

  • CELZ’s FA Score: 0 green, 5 red.
  • GNPX’s FA Score: 1 green, 4 red.
According to our system of comparison, both CELZ and GNPX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELZ’s TA Score shows that 6 TA indicator(s) are bullish while GNPX’s TA Score has 2 bullish TA indicator(s).

  • CELZ’s TA Score: 6 bullish, 4 bearish.
  • GNPX’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, CELZ is a better buy in the short-term than GNPX.

Price Growth

CELZ (@Biotechnology) experienced а +6.64% price change this week, while GNPX (@Biotechnology) price change was -4.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.17%. For the same industry, the average monthly price growth was -13.24%, and the average quarterly price growth was +5.35%.

Reported Earning Dates

CELZ is expected to report earnings on Dec 02, 2026.

Industries' Descriptions

@Biotechnology (-4.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CELZ
Daily Signal:
Gain/Loss:
GNPX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JEM3.790.11
+2.99%
707 Cayman Holdings Limited
WTTR19.840.31
+1.59%
Select Water Solutions
NBIX138.40-0.54
-0.39%
Neurocrine Biosciences
TCMD22.73-0.16
-0.70%
Tactile Systems Technology
BTCS1.53-0.10
-6.13%
BTCS

CELZ and

Correlation & Price change

A.I.dvisor tells us that CELZ and WVE have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELZ and WVE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELZ
1D Price
Change %
CELZ100%
+6.19%
WVE - CELZ
30%
Poorly correlated
-4.55%
TRDA - CELZ
29%
Poorly correlated
-0.96%
GNPX - CELZ
28%
Poorly correlated
-6.53%
IOVA - CELZ
28%
Poorly correlated
+1.85%
ACET - CELZ
26%
Poorly correlated
+9.07%
More

GNPX and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNPX has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if GNPX jumps, then CANF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNPX
1D Price
Change %
GNPX100%
-6.53%
CANF - GNPX
93%
Closely correlated
-0.37%
APVO - GNPX
86%
Closely correlated
+3.28%
ICU - GNPX
82%
Closely correlated
-0.58%
MLEC - GNPX
76%
Closely correlated
-2.69%
LONA - GNPX
76%
Closely correlated
-34.87%
More